最新临床试验：奥比妥珠单抗联合或不联合乌姆拉西布、来那度胺或联合化疗治疗复发或难治性I-IIIa级滤泡性淋巴瘤

这个一项随机对照II期临床试验研究，目的是验证奥比乌珠单抗联合或不联合乌姆拉西布、来那度胺或联合化疗对I-IIIa级滤泡性淋巴瘤复发或治疗无效患者的疗效。用单克隆抗体，如奥比乌珠单抗，进行免疫治疗可以帮助身体的免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和扩散能力。乌姆拉西布可能通过阻断细胞生长所需的一些酶来阻止癌细胞的生长。生物疗法，如来那度胺，使用由生物制成的物质，这些物质可以以不同的方式刺激或抑制免疫系统，并阻止癌细胞生长。用于化疗的药物，如环磷酰胺、盐酸阿霉素、硫酸长春新碱、强的松和苯达莫司汀，通过杀死细胞、阻止细胞分裂或阻止癌细胞扩散，以不同的方式阻止癌细胞生长。目前尚不清楚在治疗I-IIIa级滤泡性淋巴瘤时，给予奥比乌珠单抗联合或不联合其它药用及化疗是否有效。

本临床试验正在全美309家医院开展！

This randomized phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of the tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.

Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 309 locations

Trial Phase & Type